You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression

Article info

Article menu
Oncolytic and local immunotherapy
Original research
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression

Authors

  • Adam Nelson Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada PubMed articlesGoogle scholar articles
  • Simon Gebremeskel Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada PubMed articlesGoogle scholar articles
  • Brian D Lichty Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada PubMed articlesGoogle scholar articles
  • Brent Johnston Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, Canada Beatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Brent Johnston; brent.johnston{at}dal.ca
View Full Text

Citation

Nelson A, Gebremeskel S, Lichty BD, et al
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression
Journal for ImmunoTherapy of Cancer 2022;10:e003923. doi: 10.1136/jitc-2021-003923

Publication history

  • Accepted February 9, 2022
  • First published March 4, 2022.
Online issue publication 
October 18, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.